This week's View explores the benefit of uninterrupted direct oral anticoagulant versus uninterrupted vitamin K antagonist use for patients undergoing catheter ablation for nonvalvular atrial fibrillation; which therapy, anticoagulation or antiplatelet, is better for preventing stroke recurrence in patients with patent foramen ovale and a history of stroke or transient ischemic attack; and whether a post-procedural increase in creatine kinase-myocardial band or cardiac troponin is associated with high risk of death at 1 year in patients with stable angina undergoing percutaneous coronary intervention.

Subscribe on iTunes | Subscribe on Google Play

Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiovascular Care Team, Congenital Heart Disease and Pediatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Prevention, Stable Ischemic Heart Disease, Anticoagulation Management and Atrial Fibrillation, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Congenital Heart Disease, CHD and Pediatrics and Arrhythmias, CHD and Pediatrics and Interventions, CHD and Pediatrics and Prevention, CHD and Pediatrics and Quality Improvement, Interventions and Structural Heart Disease, Interventions and Vascular Medicine, Chronic Angina

Keywords: EaglesEyeView, Angina, Stable, Anticoagulants, Arrhythmias, Cardiac, Biomarkers, Atrial Fibrillation, Catheter Ablation, Cerebral Infarction, Comorbidity, Creatine Kinase, MB Form, Drug-Eluting Stents, Foramen Ovale, Patent, Heart Defects, Congenital, Hemorrhage, Heparin, Ischemic Attack, Transient, Myocardium, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Risk, Secondary Prevention, Stroke, Thromboembolism, Troponin, Vascular Diseases, Vitamin K, Warfarin

< Back to Listings